AMO Pharma to Evaluate AMO-02 in Registrational Study for Congenital Myotonic Dystrophy Type 1

AMO Pharma plans to initiate a registrational clinical study for its investigational drug, AMO-02, targeting congenital myotonic dystrophy type 1 (CDM1). The study design follows scientific advice received from the U.S. Food and Drug Administration (FDA), the UK's Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada.

The forthcoming study will assess hospitalization as the primary outcome measure, supplemented by multiple functional assessments as secondary endpoints. This approach is directly influenced by the regulatory agencies' feedback, aiming to confirm the drug's efficacy on clinically meaningful measures for patients.

Congenital myotonic dystrophy type 1 is a rare, inherited neuromuscular disorder affecting muscle contraction and relaxation. It can lead to significant challenges with breathing, swallowing, and overall development.

In March 2024, AMO Pharma held meetings with these regulatory bodies to discuss the development program for AMO-02. The objective was to ensure alignment on the requirements for a pivotal registrational study to support potential marketing authorization.

The company expects to finalize preparations and commence the trial in the near future. The outcomes of this study will be critical for the potential approval of AMO-02 as a treatment option for individuals with CDM1.